Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC.
Saddawi-Konefka R, O'Farrell A, Faraji F, Clubb L, Allevato MM, Jensen SM, Yung BS, Wang Z, Wu VH, Anang NA, Msari RA, Schokrpur S, Pietryga IF, Molinolo AA, Mesirov JP, Simon AB, Fox BA, Bui JD, Sharabi A, Cohen EEW, Califano JA, Gutkind JS.
Saddawi-Konefka R, et al. Among authors: faraji f.
Nat Commun. 2022 Jul 25;13(1):4298. doi: 10.1038/s41467-022-31941-w.
Nat Commun. 2022.
PMID: 35879302
Free PMC article.